KR20180081528A - 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅 - Google Patents
심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅 Download PDFInfo
- Publication number
- KR20180081528A KR20180081528A KR1020187014477A KR20187014477A KR20180081528A KR 20180081528 A KR20180081528 A KR 20180081528A KR 1020187014477 A KR1020187014477 A KR 1020187014477A KR 20187014477 A KR20187014477 A KR 20187014477A KR 20180081528 A KR20180081528 A KR 20180081528A
- Authority
- KR
- South Korea
- Prior art keywords
- treatment
- alx
- fpr2
- receptor
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259498P | 2015-11-24 | 2015-11-24 | |
| US62/259,498 | 2015-11-24 | ||
| PCT/US2016/063036 WO2017091496A1 (en) | 2015-11-24 | 2016-11-21 | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180081528A true KR20180081528A (ko) | 2018-07-16 |
Family
ID=57544530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187014477A Withdrawn KR20180081528A (ko) | 2015-11-24 | 2016-11-21 | 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180325869A1 (https=) |
| EP (1) | EP3380091A1 (https=) |
| JP (1) | JP2018538367A (https=) |
| KR (1) | KR20180081528A (https=) |
| CN (1) | CN108348479A (https=) |
| AU (1) | AU2016359463A1 (https=) |
| BR (1) | BR112018010155A8 (https=) |
| CA (1) | CA3006291A1 (https=) |
| EA (1) | EA201891007A1 (https=) |
| IL (1) | IL259468A (https=) |
| MX (1) | MX2018005756A (https=) |
| SG (1) | SG11201803816RA (https=) |
| WO (1) | WO2017091496A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3414227B1 (en) | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227067A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110997653B (zh) | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
| US11008301B2 (en) | 2017-06-09 | 2021-05-18 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US10676431B2 (en) | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| IL299680A (en) | 2020-07-09 | 2023-03-01 | Bristol Myers Squibb Co | Pyrazolone formyl peptide 2 receptor agonists |
| JP7802765B2 (ja) | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2492167C2 (ru) * | 2007-12-18 | 2013-09-10 | Актелион Фармасьютиклз Лтд | Производные аминотриазола в качестве агонистов alх |
| KR101905927B1 (ko) * | 2010-11-17 | 2018-10-08 | 이도르시아 파마슈티컬스 리미티드 | 가교된 스피로［２．４］헵탄 에스테르 유도체 |
| CA2871334A1 (en) * | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| EP3414227B1 (en) * | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| US10676431B2 (en) * | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
-
2016
- 2016-11-21 CN CN201680068442.7A patent/CN108348479A/zh active Pending
- 2016-11-21 WO PCT/US2016/063036 patent/WO2017091496A1/en not_active Ceased
- 2016-11-21 MX MX2018005756A patent/MX2018005756A/es unknown
- 2016-11-21 AU AU2016359463A patent/AU2016359463A1/en not_active Abandoned
- 2016-11-21 EA EA201891007A patent/EA201891007A1/ru unknown
- 2016-11-21 EP EP16810536.9A patent/EP3380091A1/en not_active Withdrawn
- 2016-11-21 JP JP2018545568A patent/JP2018538367A/ja not_active Withdrawn
- 2016-11-21 KR KR1020187014477A patent/KR20180081528A/ko not_active Withdrawn
- 2016-11-21 BR BR112018010155A patent/BR112018010155A8/pt not_active Application Discontinuation
- 2016-11-21 CA CA3006291A patent/CA3006291A1/en not_active Abandoned
- 2016-11-21 US US15/776,927 patent/US20180325869A1/en not_active Abandoned
- 2016-11-21 SG SG11201803816RA patent/SG11201803816RA/en unknown
-
2018
- 2018-05-17 IL IL259468A patent/IL259468A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180325869A1 (en) | 2018-11-15 |
| CA3006291A1 (en) | 2017-06-01 |
| EP3380091A1 (en) | 2018-10-03 |
| BR112018010155A8 (pt) | 2019-02-26 |
| WO2017091496A1 (en) | 2017-06-01 |
| SG11201803816RA (en) | 2018-06-28 |
| MX2018005756A (es) | 2018-08-01 |
| CN108348479A (zh) | 2018-07-31 |
| IL259468A (en) | 2018-07-31 |
| JP2018538367A (ja) | 2018-12-27 |
| EA201891007A1 (ru) | 2018-11-30 |
| AU2016359463A1 (en) | 2018-07-12 |
| BR112018010155A2 (pt) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180081528A (ko) | 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅 | |
| Carbone et al. | Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury | |
| US20210000762A1 (en) | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases | |
| EA021303B1 (ru) | Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста | |
| KR20200006595A (ko) | 심부전 치료를 위한 포르밀 펩티드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 효능제의 신규 용도 | |
| Zempo et al. | A P2X7 receptor antagonist attenuates experimental autoimmune myocarditis via suppressed myocardial CD4+ T and macrophage infiltration and NADPH oxidase 2/4 expression in mice | |
| EP2882431A1 (en) | Probenecid for treating cardiomyopathy, systolic cardiac dysfunction and the symptoms of congestive heart failure | |
| US11524055B2 (en) | Methods for treating diseases mediated by ERBB4-positive pro-inflammatory macrophages | |
| KR102354243B1 (ko) | 트롬복산-a2 수용체 길항제를 이용한 근위축증 치료 조성물 및 방법 | |
| US20200009146A1 (en) | Autophagy inducers for treatment of cns conditions | |
| US12226455B2 (en) | Medical composition for treating cardiac wasting and cachexia | |
| US11311600B2 (en) | Methods for treating obesity | |
| JPWO2016080516A1 (ja) | Ｄｒｐ１重合阻害剤 | |
| US20230114408A1 (en) | Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists | |
| JP2017109987A (ja) | ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法 | |
| EP4117660B1 (en) | Methods of modulating t-cell activation and treating chronic heart failure using carboranes | |
| CN111329867A (zh) | 一种1,25-(oh)2d3在制备治疗心力衰竭药物中的应用 | |
| JP2022516611A (ja) | 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体 | |
| US20200277264A1 (en) | Compounds for Treating Disorders Associated with Abnormal Steroidogenesis | |
| WO2026064493A1 (en) | Inhibition of farnesyltransferase to treat cardiomyopathy and heart failure | |
| WO2026057747A1 (en) | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds | |
| US20220054485A1 (en) | Methods of treating right ventricular function in pulmonary hypertension | |
| HK40080138A (en) | Methods of modulating t-cell activation using carboranes and carborane analogs | |
| KR20250157553A (ko) | 성장 호르몬 분비 촉진제 | |
| WO2025056188A1 (en) | Relaxin medication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180523 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |